Jaguar Health Inc. (JAGX)
NASDAQ: JAGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
JAGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.03M
- EPS (TTM)
- -$257.15
- Dividend yield
- None
- 52-week range
- 0.22 – 981.75
- Day range
- 0.22 – 0.3278
- Volume / Avg
- 987.20K / 2.40M
- Beta
- —
- Shares outstanding
- 13.35M
52-week range
JAGX stock today
Jaguar Health (JAGX) closed at $0.227 on Nov 20, down 30.58% (-$0.10), versus the S&P 500's 3.70% decline. Trading was light, with 987.20K shares changing hands, about 41% of the average daily volume. At this level, JAGX sits near the bottom of its 52-week range of $0.22 to $981.75: 100.0% below the high and 3.2% above the low.
Jaguar Health has posted a net loss over the last twelve months (EPS of -$257.15), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Jaguar Health
Company profileJaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Lisa A. Conte
- Headquarters
- San Francisco, CA
- Employees
- 47
- IPO year
- 2015
- Website
- jaguar.health
Financial highlights
Full financialsIn fiscal 2025, Jaguar Health generated $11.5 million in revenue, down 1.5% from fiscal 2024, its first annual decline since 2023. Jaguar Health reported a net loss of $53.6 million, compared with a loss of $38.5 million a year earlier. Gross margin was 67.2% (down from 83.3%) and operating margin -398.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $11.51M | $11.69M | $9.76M | $11.96M | $4.33M |
| Growth | -1.52% | +19.75% | -18.36% | +175.80% | -53.81% |
| Net income | $-53.58M | $-38.49M | $-41.90K | $-48.40K | $-52.60K |
| EPS (diluted) | $-22.97 | $-130.69 | $-2,678.17 | $-36.18 | $-88.22 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-9.23 vs —
JAGX news
All JAGX newsJaguar Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SKYESkye Bioscience Inc. | 0.70 | -11.03% | $3.10M | vs JAGX |
| APUSApimeds Pharmaceuticals US Inc. | 1.60 | -8.05% | $2.96M | vs JAGX |
| GELSGelteq Limited | 0.2701 | -3.74% | $3.11M | vs JAGX |
| AZTRAzitra Inc | 0.5168 | -2.75% | $3.13M | vs JAGX |
| MDCXMedicus Pharma Ltd. | 1.14 | -2.16% | $3.16M | vs JAGX |
| KPRXKiora Pharmaceuticals Inc. | 0.7202 | -12.28% | $3.19M | vs JAGX |
| NRSNNeuroSense Therapeutics Ltd. | 1.28 | +1.59% | $3.19M | vs JAGX |
| APREAprea Therapeutics Inc. | 0.229 | -53.56% | $3.25M | vs JAGX |
Indexes, lists and sector
Jaguar Health stock FAQ
What is Jaguar Health's stock price today?
JAGX last traded at $0.227 as of Nov 20, 4:00 PM EST, down 30.58% on the day. Prices are delayed at least 15 minutes.
Who is Jaguar Health's CEO?
Ms. Lisa A. Conte is the chief executive officer of Jaguar Health Inc., which has about 47 employees.
What is the JAGX 52-week high?
The 52-week high for JAGX is $981.75 and the 52-week low is $0.22. The stock is currently 100.0% below its high.